Glioblastoma Multiforme (GBM) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Glioblastoma Multiforme (GBM) – Pipeline Review, H2 2016’, provides an overview of the Glioblastoma Multiforme (GBM) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM)

The report reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Glioblastoma Multiforme (GBM) therapeutics and enlists all their major and minor projects

The report assesses Glioblastoma Multiforme (GBM) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Glioblastoma Multiforme (GBM)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Activartis Biotech GmbH

Advanced Accelerator Applications SA

Advantagene Inc

Advenchen Laboratories LLC

Affimed GmbH

Agenus Inc

Amal Therapeutics SA

Ambrx Inc

Amgen Inc

Ampio Pharmaceuticals Inc

AngioChem Inc

Apac Biotech Pvt Ltd

Apceth GmbH & Co KG

APIM Therapeutics AS

Apogenix GmbH

Ariad Pharmaceuticals Inc

Arog Pharmaceuticals Inc

Astellas Pharma Inc

AstraZeneca Plc

Athenex Inc

Axelar AB

Basilea Pharmaceutica Ltd

Batu Biologics Inc

Bayer AG

BeiGene Ltd

Bexion Pharmaceuticals LLC

BeyondSpring Pharmaceuticals Inc

Bio-Path Holdings Inc

Bioasis Technologies Inc

BioCancell Ltd

Biomar Microbial Technologies

Bioncotech Therapeutics SL

Biovista Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

BTG Plc

Cantex Pharmaceuticals Inc

Cavion LLC

Celgene Corp

Cell Medica Ltd

Celldex Therapeutics Inc

Celsion Corp

ChemoCentryx Inc

CLL Pharma SA

Coherus BioSciences Inc

Cortice Biosciences Inc

Critical Outcome Technologies Inc

CTI BioPharma Corp

Curadev Pharma Pvt Ltd

Cynata Therapeutics Limited

CytoVac A/S

CytRx Corp

Deciphera Pharmaceuticals LLC

DEKK-TEC Inc

DelMar Pharmaceuticals Inc

Diffusion Pharmaceuticals Inc

Dr. Reddy's Laboratories Ltd

Ecrins Therapeutics SAS

EirGenix Inc

Eisai Co Ltd

Eli Lilly and Company

EnGeneIC Ltd

EntreChem SL

ERC Belgium SA

Evotec AG

F. Hoffmann-La Roche Ltd

FirstString Research Inc

Five Prime Therapeutics Inc

Gene Techno Science Co Ltd

Genentech Inc

Genisphere Inc

Genor BioPharma Co Ltd

Genzyme Corp

GlaxoSmithKline Plc

GtreeBNT Co Ltd

GW Pharmaceuticals Plc

Hamlet Pharma AB

Hutchison MediPharma Ltd

Immatics Biotechnologies GmbH

Immune Pharmaceuticals Inc

ImmunoCellular Therapeutics Ltd

Immunomedics Inc

Immunomet Therapeutics Inc

Immunomic Therapeutics Inc

Immupharma Plc

Incuron LLC

Incyte Corp

Infinity Pharmaceuticals Inc

Inspyr Therapeutics Inc

INSYS Therapeutics Inc

Intica Biomedical Inc

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Kadmon Corp LLC

Kalgene Pharmaceuticals Inc

KaloBios Pharmaceuticals Inc

Karyopharm Therapeutics Inc

Kite Pharma Inc

Komipharm International Co Ltd

Lentigen Technology Inc

Les Laboratoires Servier SAS

LinXis BV

Lion Biotechnologies Inc

Lixte Biotechnology Holdings Inc

Loxo Oncology, Inc.

Mabion SA

MacroGenics Inc

Mateon Therapeutics Inc

Medicenna Therapeutics Inc

MedImmune LLC

Merck & Co Inc

Merck KGaA

Midatech Pharma Plc

Millennium Pharmaceuticals Inc

MimiVax LLC

Moleculin Biotech Inc

Mycenax Biotech Inc

Nanomerics Ltd

Neonc Technologies Inc

Nerviano Medical Sciences Srl

Neumedicines Inc

Neuralstem Inc

NewLink Genetics Corp

Northwest Biotherapeutics Inc

Novartis AG

Novogen Ltd

Noxxon Pharma AG

Nuo Therapeutics Inc

NuvOx Pharma LLC

Omniox Inc

Oncobiologics Inc

Oncodesign SA

Onconova Therapeutics Inc

Oncternal Therapeutics Inc

Ono Pharmaceutical Co Ltd

Orphagen Pharmaceuticals Inc

Orphit SAS

Oryx GmbH & Co KG

Peloton Therapeutics Inc

Peregrine Pharmaceuticals Inc

Pfizer Inc

PharmAbcine Inc

PharmaCyte Biotech Inc

Pharmicell Co Ltd

PIQUR Therapeutics AG

Plex Pharmaceuticals Inc

Plexxikon Inc

Prana Biotechnology Ltd

Progenics Pharmaceuticals Inc

Puma Biotechnology Inc

Recepta Biopharma SA

Regulus Therapeutics Inc

ReNeuron Group Plc

Rexahn Pharmaceuticals Inc

Rgenix Inc

Richter Gedeon Nyrt

Rigontec GmbH

Sanofi

Sapience Therapeutics Inc

Scancell Holdings Plc

Sellas Inc

Sigma-Tau SpA

SignPath Pharma Inc

SOM Biotech SL

Sorrento Therapeutics Inc

StemGen SpA

Stemline Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Susavion Biosciences Inc

Symphogen A/S

Takeda Pharmaceutical Company Ltd

Terpenoid Therapeutics Inc

Therapeia GmbH & Co KG

Theravectys SA

Threshold Pharmaceuticals Inc

Tocagen Inc

TRACON Pharmaceuticals Inc

Transgene SA

Trillium Therapeutics Inc

TVAX Biomedical Inc

Tyme Technologies Inc

Upsher-Smith Laboratories Inc

Vascular Biogenics Ltd

Vault Pharma Inc

Vaximm AG

VBI Vaccines Inc

VCN Biosciences SL

Vertex Pharmaceuticals Inc

ViraTherapeutics GmbH

Virttu Biologics Ltd

Vyriad Inc

X4 Pharmaceuticals Inc

ZIOPHARM Oncology Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 10

Glioblastoma Multiforme (GBM) Overview 11

Therapeutics Development 12

Glioblastoma Multiforme (GBM) - Therapeutics under Development by Companies 14

Glioblastoma Multiforme (GBM) - Therapeutics under Investigation by Universities/Institutes 32

Glioblastoma Multiforme (GBM) - Pipeline Products Glance 35

Glioblastoma Multiforme (GBM) - Products under Development by Companies 39

Glioblastoma Multiforme (GBM) - Products under Investigation by Universities/Institutes 61

Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development 65

Glioblastoma Multiforme (GBM) - Therapeutics Assessment 260

Drug Profiles 302

Glioblastoma Multiforme (GBM) - Dormant Projects 1242

Glioblastoma Multiforme (GBM) - Discontinued Products 1259

Glioblastoma Multiforme (GBM) - Product Development Milestones 1262

Appendix 1278

List of Tables

List of Tables

Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2016 54

Number of Products under Development for Glioblastoma Multiforme (GBM) – Comparative Analysis, H2 2016 55

Number of Products under Development by Companies, H2 2016 57

Number of Products under Development by Companies, H2 2016 (Contd..1) 58

Number of Products under Development by Companies, H2 2016 (Contd..2) 59

Number of Products under Development by Companies, H2 2016 (Contd..3) 60

Number of Products under Development by Companies, H2 2016 (Contd..4) 61

Number of Products under Development by Companies, H2 2016 (Contd..5) 62

Number of Products under Development by Companies, H2 2016 (Contd..6) 63

Number of Products under Development by Companies, H2 2016 (Contd..7) 64

Number of Products under Development by Companies, H2 2016 (Contd..8) 65

Number of Products under Development by Companies, H2 2016 (Contd..9) 66

Number of Products under Development by Companies, H2 2016 (Contd..10) 67

Number of Products under Development by Companies, H2 2016 (Contd..11) 68

Number of Products under Development by Companies, H2 2016 (Contd..12) 69

Number of Products under Development by Companies, H2 2016 (Contd..13) 70

Number of Products under Development by Companies, H2 2016 (Contd..14) 71

Number of Products under Development by Companies, H2 2016 (Contd..15) 72

Number of Products under Development by Companies, H2 2016 (Contd..16) 73

Number of Products under Investigation by Universities/Institutes, H2 2016 74

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 75

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 76

Comparative Analysis by Late Stage Development, H2 2016 77

Comparative Analysis by Clinical Stage Development, H2 2016 78

Comparative Analysis by Early Stage Development, H2 2016 79

Comparative Analysis by Unknown Stage Development, H2 2016 80

Products under Development by Companies, H2 2016 81

Products under Development by Companies, H2 2016 (Contd..1) 82

Products under Development by Companies, H2 2016 (Contd..2) 83

Products under Development by Companies, H2 2016 (Contd..3) 84

Products under Development by Companies, H2 2016 (Contd..4) 85

Products under Development by Companies, H2 2016 (Contd..5) 86

Products under Development by Companies, H2 2016 (Contd..6) 87

Products under Development by Companies, H2 2016 (Contd..7) 88

Products under Development by Companies, H2 2016 (Contd..8) 89

Products under Development by Companies, H2 2016 (Contd..9) 90

Products under Development by Companies, H2 2016 (Contd..10) 91

Products under Development by Companies, H2 2016 (Contd..11) 92

Products under Development by Companies, H2 2016 (Contd..12) 93

Products under Development by Companies, H2 2016 (Contd..13) 94

Products under Development by Companies, H2 2016 (Contd..14) 95

Products under Development by Companies, H2 2016 (Contd..15) 96

Products under Development by Companies, H2 2016 (Contd..16) 97

Products under Development by Companies, H2 2016 (Contd..17) 98

Products under Development by Companies, H2 2016 (Contd..18) 99

Products under Development by Companies, H2 2016 (Contd..19) 100

Products under Development by Companies, H2 2016 (Contd..20) 101

Products under Development by Companies, H2 2016 (Contd..21) 102

Products under Investigation by Universities/Institutes, H2 2016 103

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 104

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 105

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 106

Glioblastoma Multiforme (GBM) – Pipeline by AbbVie Inc, H2 2016 107

Glioblastoma Multiforme (GBM) – Pipeline by Activartis Biotech GmbH, H2 2016 108

Glioblastoma Multiforme (GBM) – Pipeline by Advanced Accelerator Applications SA, H2 2016 109

Glioblastoma Multiforme (GBM) – Pipeline by Advantagene Inc, H2 2016 110

Glioblastoma Multiforme (GBM) – Pipeline by Advenchen Laboratories LLC, H2 2016 111

Glioblastoma Multiforme (GBM) – Pipeline by Affimed GmbH, H2 2016 112

Glioblastoma Multiforme (GBM) – Pipeline by Agenus Inc, H2 2016 113

Glioblastoma Multiforme (GBM) – Pipeline by Amal Therapeutics SA, H2 2016 114

Glioblastoma Multiforme (GBM) – Pipeline by Ambrx Inc, H2 2016 115

Glioblastoma Multiforme (GBM) – Pipeline by Amgen Inc, H2 2016 116

Glioblastoma Multiforme (GBM) – Pipeline by Ampio Pharmaceuticals Inc, H2 2016 117

Glioblastoma Multiforme (GBM) – Pipeline by AngioChem Inc, H2 2016 118

Glioblastoma Multiforme (GBM) – Pipeline by Apac Biotech Pvt Ltd, H2 2016 119

Glioblastoma Multiforme (GBM) – Pipeline by Apceth GmbH & Co KG, H2 2016 120

Glioblastoma Multiforme (GBM) – Pipeline by APIM Therapeutics AS, H2 2016 121

Glioblastoma Multiforme (GBM) – Pipeline by Apogenix GmbH, H2 2016 122

Glioblastoma Multiforme (GBM) – Pipeline by Ariad Pharmaceuticals Inc, H2 2016 123

Glioblastoma Multiforme (GBM) – Pipeline by Arog Pharmaceuticals Inc, H2 2016 124

Glioblastoma Multiforme (GBM) – Pipeline by Astellas Pharma Inc, H2 2016 125

Glioblastoma Multiforme (GBM) – Pipeline by AstraZeneca Plc, H2 2016 126

Glioblastoma Multiforme (GBM) – Pipeline by Athenex Inc, H2 2016 127

Glioblastoma Multiforme (GBM) – Pipeline by Axelar AB, H2 2016 128

Glioblastoma Multiforme (GBM) – Pipeline by Basilea Pharmaceutica Ltd, H2 2016 129

Glioblastoma Multiforme (GBM) – Pipeline by Batu Biologics Inc, H2 2016 130

Glioblastoma Multiforme (GBM) – Pipeline by Bayer AG, H2 2016 131

Glioblastoma Multiforme (GBM) – Pipeline by BeiGene Ltd, H2 2016 132

Glioblastoma Multiforme (GBM) – Pipeline by Bexion Pharmaceuticals LLC, H2 2016 133

Glioblastoma Multiforme (GBM) – Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2016 134

Glioblastoma Multiforme (GBM) – Pipeline by Bio-Path Holdings Inc, H2 2016 135

Glioblastoma Multiforme (GBM) – Pipeline by Bioasis Technologies Inc, H2 2016 136

Glioblastoma Multiforme (GBM) – Pipeline by BioCancell Ltd, H2 2016 137

Glioblastoma Multiforme (GBM) – Pipeline by Biomar Microbial Technologies, H2 2016 138

Glioblastoma Multiforme (GBM) – Pipeline by Bioncotech Therapeutics SL, H2 2016 139

Glioblastoma Multiforme (GBM) – Pipeline by Biovista Inc, H2 2016 140

Glioblastoma Multiforme (GBM) – Pipeline by Boehringer Ingelheim GmbH, H2 2016 141

Glioblastoma Multiforme (GBM) – Pipeline by Boston Biomedical Inc, H2 2016 142

Glioblastoma Multiforme (GBM) – Pipeline by Bristol-Myers Squibb Company, H2 2016 143

Glioblastoma Multiforme (GBM) – Pipeline by BTG Plc, H2 2016 144

Glioblastoma Multiforme (GBM) – Pipeline by Cantex Pharmaceuticals Inc, H2 2016 145

Glioblastoma Multiforme (GBM) – Pipeline by Cavion LLC, H2 2016 146

Glioblastoma Multiforme (GBM) – Pipeline by Celgene Corp, H2 2016 147

Glioblastoma Multiforme (GBM) – Pipeline by Cell Medica Ltd, H2 2016 148

Glioblastoma Multiforme (GBM) – Pipeline by Celldex Therapeutics Inc, H2 2016 149

Glioblastoma Multiforme (GBM) – Pipeline by Celsion Corp, H2 2016 150

Glioblastoma Multiforme (GBM) – Pipeline by ChemoCentryx Inc, H2 2016 151

Glioblastoma Multiforme (GBM) – Pipeline by CLL Pharma SA, H2 2016 152

Glioblastoma Multiforme (GBM) – Pipeline by Coherus BioSciences Inc, H2 2016 153

Glioblastoma Multiforme (GBM) – Pipeline by Cortice Biosciences Inc, H2 2016 154

Glioblastoma Multiforme (GBM) – Pipeline by Critical Outcome Technologies Inc, H2 2016 155

Glioblastoma Multiforme (GBM) – Pipeline by CTI BioPharma Corp, H2 2016 156

Glioblastoma Multiforme (GBM) – Pipeline by Curadev Pharma Pvt Ltd, H2 2016 157

Glioblastoma Multiforme (GBM) – Pipeline by Cynata Therapeutics Limited, H2 2016 158

Glioblastoma Multiforme (GBM) – Pipeline by CytoVac A/S, H2 2016 159

Glioblastoma Multiforme (GBM) – Pipeline by CytRx Corp, H2 2016 160

Glioblastoma Multiforme (GBM) – Pipeline by Deciphera Pharmaceuticals LLC, H2 2016 161

Glioblastoma Multiforme (GBM) – Pipeline by DEKK-TEC Inc, H2 2016 162

Glioblastoma Multiforme (GBM) – Pipeline by DelMar Pharmaceuticals Inc, H2 2016 163

Glioblastoma Multiforme (GBM) – Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 164

Glioblastoma Multiforme (GBM) – Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 165

Glioblastoma Multiforme (GBM) – Pipeline by Ecrins Therapeutics SAS, H2 2016 166

Glioblastoma Multiforme (GBM) – Pipeline by EirGenix Inc, H2 2016 167

Glioblastoma Multiforme (GBM) – Pipeline by Eisai Co Ltd, H2 2016 168

Glioblastoma Multiforme (GBM) – Pipeline by Eli Lilly and Company, H2 2016 169

Glioblastoma Multiforme (GBM) – Pipeline by EnGeneIC Ltd, H2 2016 170

Glioblastoma Multiforme (GBM) – Pipeline by EntreChem SL, H2 2016 171

Glioblastoma Multiforme (GBM) – Pipeline by ERC Belgium SA, H2 2016 172

Glioblastoma Multiforme (GBM) – Pipeline by Evotec AG, H2 2016 173

Glioblastoma Multiforme (GBM) – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 174

Glioblastoma Multiforme (GBM) – Pipeline by FirstString Research Inc, H2 2016 175

Glioblastoma Multiforme (GBM) – Pipeline by Five Prime Therapeutics Inc, H2 2016 176

Glioblastoma Multiforme (GBM) – Pipeline by Gene Techno Science Co Ltd, H2 2016 177

Glioblastoma Multiforme (GBM) – Pipeline by Genentech Inc, H2 2016 178

Glioblastoma Multiforme (GBM) – Pipeline by Genisphere Inc, H2 2016 179

Glioblastoma Multiforme (GBM) – Pipeline by Genor BioPharma Co Ltd, H2 2016 180

Glioblastoma Multiforme (GBM) – Pipeline by Genzyme Corp, H2 2016 181

Glioblastoma Multiforme (GBM) – Pipeline by GlaxoSmithKline Plc, H2 2016 182

Glioblastoma Multiforme (GBM) – Pipeline by GtreeBNT Co Ltd, H2 2016 183

Glioblastoma Multiforme (GBM) – Pipeline by GW Pharmaceuticals Plc, H2 2016 184

Glioblastoma Multiforme (GBM) – Pipeline by Hamlet Pharma AB, H2 2016 185

Glioblastoma Multiforme (GBM) – Pipeline by Hutchison MediPharma Ltd, H2 2016 186

Glioblastoma Multiforme (GBM) – Pipeline by Immatics Biotechnologies GmbH, H2 2016 187

Glioblastoma Multiforme (GBM) – Pipeline by Immune Pharmaceuticals Inc, H2 2016 188

Glioblastoma Multiforme (GBM) – Pipeline by ImmunoCellular Therapeutics Ltd, H2 2016 189

Glioblastoma Multiforme (GBM) – Pipeline by Immunomedics Inc, H2 2016 190

Glioblastoma Multiforme (GBM) – Pipeline by Immunomet Therapeutics Inc, H2 2016 191

Glioblastoma Multiforme (GBM) – Pipeline by Immunomic Therapeutics Inc, H2 2016 192

Glioblastoma Multiforme (GBM) – Pipeline by Immupharma Plc, H2 2016 193

Glioblastoma Multiforme (GBM) – Pipeline by Incuron LLC, H2 2016 194

Glioblastoma Multiforme (GBM) – Pipeline by Incyte Corp, H2 2016 195

Glioblastoma Multiforme (GBM) – Pipeline by Infinity Pharmaceuticals Inc, H2 2016 196

Glioblastoma Multiforme (GBM) – Pipeline by Inspyr Therapeutics Inc, H2 2016 197

Glioblastoma Multiforme (GBM) – Pipeline by INSYS Therapeutics Inc, H2 2016 198

Glioblastoma Multiforme (GBM) – Pipeline by Intica Biomedical Inc, H2 2016 199

Glioblastoma Multiforme (GBM) – Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2016 200

Glioblastoma Multiforme (GBM) – Pipeline by Johnson & Johnson, H2 2016 201

Glioblastoma Multiforme (GBM) – Pipeline by Kadmon Corp LLC, H2 2016 202

Glioblastoma Multiforme (GBM) – Pipeline by Kalgene Pharmaceuticals Inc, H2 2016 203

Glioblastoma Multiforme (GBM) – Pipeline by KaloBios Pharmaceuticals Inc, H2 2016 204

Glioblastoma Multiforme (GBM) – Pipeline by Karyopharm Therapeutics Inc, H2 2016 205

Glioblastoma Multiforme (GBM) – Pipeline by Kite Pharma Inc, H2 2016 206

Glioblastoma Multiforme (GBM) – Pipeline by Komipharm International Co Ltd, H2 2016 207

Glioblastoma Multiforme (GBM) – Pipeline by Lentigen Technology Inc, H2 2016 208

Glioblastoma Multiforme (GBM) – Pipeline by Les Laboratoires Servier SAS, H2 2016 209

Glioblastoma Multiforme (GBM) – Pipeline by LinXis BV, H2 2016 210

Glioblastoma Multiforme (GBM) – Pipeline by Lion Biotechnologies Inc, H2 2016 211

Glioblastoma Multiforme (GBM) – Pipeline by Lixte Biotechnology Holdings Inc, H2 2016 212

Glioblastoma Multiforme (GBM) – Pipeline by Loxo Oncology, Inc., H2 2016 213

Glioblastoma Multiforme (GBM) – Pipeline by Mabion SA, H2 2016 214

Glioblastoma Multiforme (GBM) – Pipeline by MacroGenics Inc, H2 2016 215

Glioblastoma Multiforme (GBM) – Pipeline by Mateon Therapeutics Inc, H2 2016 216

Glioblastoma Multiforme (GBM) – Pipeline by Medicenna Therapeutics Inc, H2 2016 217

Glioblastoma Multiforme (GBM) – Pipeline by MedImmune LLC, H2 2016 218

Glioblastoma Multiforme (GBM) – Pipeline by Merck & Co Inc, H2 2016 219

Glioblastoma Multiforme (GBM) – Pipeline by Merck KGaA, H2 2016 220

Glioblastoma Multiforme (GBM) – Pipeline by Midatech Pharma Plc, H2 2016 221

Glioblastoma Multiforme (GBM) – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 222

Glioblastoma Multiforme (GBM) – Pipeline by MimiVax LLC, H2 2016 223

Glioblastoma Multiforme (GBM) – Pipeline by Moleculin Biotech Inc, H2 2016 224

Glioblastoma Multiforme (GBM) – Pipeline by Mycenax Biotech Inc, H2 2016 225

Glioblastoma Multiforme (GBM) – Pipeline by Nanomerics Ltd, H2 2016 226

Glioblastoma Multiforme (GBM) – Pipeline by Neonc Technologies Inc, H2 2016 227

Glioblastoma Multiforme (GBM) – Pipeline by Nerviano Medical Sciences Srl, H2 2016 228

Glioblastoma Multiforme (GBM) – Pipeline by Neumedicines Inc, H2 2016 229

Glioblastoma Multiforme (GBM) – Pipeline by Neuralstem Inc, H2 2016 230

Glioblastoma Multiforme (GBM) – Pipeline by NewLink Genetics Corp, H2 2016 231

Glioblastoma Multiforme (GBM) – Pipeline by Northwest Biotherapeutics Inc, H2 2016 232

Glioblastoma Multiforme (GBM) – Pipeline by Novartis AG, H2 2016 233

Glioblastoma Multiforme (GBM) – Pipeline by Novogen Ltd, H2 2016 234

Glioblastoma Multiforme (GBM) – Pipeline by Noxxon Pharma AG, H2 2016 235

Glioblastoma Multiforme (GBM) – Pipeline by Nuo Therapeutics Inc, H2 2016 236

Glioblastoma Multiforme (GBM) – Pipeline by NuvOx Pharma LLC, H2 2016 237

Glioblastoma Multiforme (GBM) – Pipeline by Omniox Inc, H2 2016 238

Glioblastoma Multiforme (GBM) – Pipeline by Oncobiologics Inc, H2 2016 239

Glioblastoma Multiforme (GBM) – Pipeline by Oncodesign SA, H2 2016 240

Glioblastoma Multiforme (GBM) – Pipeline by Onconova Therapeutics Inc, H2 2016 241

Glioblastoma Multiforme (GBM) – Pipeline by Oncternal Therapeutics Inc, H2 2016 242

Glioblastoma Multiforme (GBM) – Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 243

Glioblastoma Multiforme (GBM) – Pipeline by Orphagen Pharmaceuticals Inc, H2 2016 244

Glioblastoma Multiforme (GBM) – Pipeline by Orphit SAS, H2 2016 245

Glioblastoma Multiforme (GBM) – Pipeline by Oryx GmbH & Co KG, H2 2016 246

Glioblastoma Multiforme (GBM) – Pipeline by Peloton Therapeutics Inc, H2 2016 247

Glioblastoma Multiforme (GBM) – Pipeline by Peregrine Pharmaceuticals Inc, H2 2016 248

Glioblastoma Multiforme (GBM) – Pipeline by Pfizer Inc, H2 2016 249

Glioblastoma Multiforme (GBM) – Pipeline by PharmAbcine Inc, H2 2016 250

Glioblastoma Multiforme (GBM) – Pipeline by PharmaCyte Biotech Inc, H2 2016 251

Glioblastoma Multiforme (GBM) – Pipeline by Pharmicell Co Ltd, H2 2016 252

Glioblastoma Multiforme (GBM) – Pipeline by PIQUR Therapeutics AG, H2 2016 253

Glioblastoma Multiforme (GBM) – Pipeline by Plex Pharmaceuticals Inc, H2 2016 254

Glioblastoma Multiforme (GBM) – Pipeline by Plexxikon Inc, H2 2016 255

Glioblastoma Multiforme (GBM) – Pipeline by Prana Biotechnology Ltd, H2 2016 256

Glioblastoma Multiforme (GBM) – Pipeline by Progenics Pharmaceuticals Inc, H2 2016 257

Glioblastoma Multiforme (GBM) – Pipeline by Puma Biotechnology Inc, H2 2016 258

Glioblastoma Multiforme (GBM) – Pipeline by Recepta Biopharma SA, H2 2016 259

Glioblastoma Multiforme (GBM) – Pipeline by Regulus Therapeutics Inc, H2 2016 260

Glioblastoma Multiforme (GBM) – Pipeline by ReNeuron Group Plc, H2 2016 261

Glioblastoma Multiforme (GBM) – Pipeline by Rexahn Pharmaceuticals Inc, H2 2016 262

Glioblastoma Multiforme (GBM) – Pipeline by Rgenix Inc, H2 2016 263

Glioblastoma Multiforme (GBM) – Pipeline by Richter Gedeon Nyrt, H2 2016 264

Glioblastoma Multiforme (GBM) – Pipeline by Rigontec GmbH, H2 2016 265

Glioblastoma Multiforme (GBM) – Pipeline by Sanofi, H2 2016 266

Glioblastoma Multiforme (GBM) – Pipeline by Sapience Therapeutics Inc, H2 2016 267

Glioblastoma Multiforme (GBM) – Pipeline by Scancell Holdings Plc, H2 2016 268

Glioblastoma Multiforme (GBM) – Pipeline by Sellas Inc, H2 2016 269

Glioblastoma Multiforme (GBM) – Pipeline by Sigma-Tau SpA, H2 2016 270

Glioblastoma Multiforme (GBM) – Pipeline by SignPath Pharma Inc, H2 2016 271

Glioblastoma Multiforme (GBM) – Pipeline by SOM Biotech SL, H2 2016 272

Glioblastoma Multiforme (GBM) – Pipeline by Sorrento Therapeutics Inc, H2 2016 273

Glioblastoma Multiforme (GBM) – Pipeline by StemGen SpA, H2 2016 274

Glioblastoma Multiforme (GBM) – Pipeline by Stemline Therapeutics Inc, H2 2016 275

Glioblastoma Multiforme (GBM) – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 276

Glioblastoma Multiforme (GBM) – Pipeline by Susavion Biosciences Inc, H2 2016 277

Glioblastoma Multiforme (GBM) – Pipeline by Symphogen A/S, H2 2016 278

Glioblastoma Multiforme (GBM) – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 279

Glioblastoma Multiforme (GBM) – Pipeline by Terpenoid Therapeutics Inc, H2 2016 280

Glioblastoma Multiforme (GBM) – Pipeline by Therapeia GmbH & Co KG, H2 2016 281

Glioblastoma Multiforme (GBM) – Pipeline by Theravectys SA, H2 2016 282

Glioblastoma Multiforme (GBM) – Pipeline by Threshold Pharmaceuticals Inc, H2 2016 283

Glioblastoma Multiforme (GBM) – Pipeline by Tocagen Inc, H2 2016 284

Glioblastoma Multiforme (GBM) – Pipeline by TRACON Pharmaceuticals Inc, H2 2016 285

Glioblastoma Multiforme (GBM) – Pipeline by Transgene SA, H2 2016 286

Glioblastoma Multiforme (GBM) – Pipeline by Trillium Therapeutics Inc, H2 2016 287

Glioblastoma Multiforme (GBM) – Pipeline by TVAX Biomedical Inc, H2 2016 288

Glioblastoma Multiforme (GBM) – Pipeline by Tyme Technologies Inc, H2 2016 289

Glioblastoma Multiforme (GBM) – Pipeline by Upsher-Smith Laboratories Inc, H2 2016 290

Glioblastoma Multiforme (GBM) – Pipeline by Vascular Biogenics Ltd, H2 2016 291

Glioblastoma Multiforme (GBM) – Pipeline by Vault Pharma Inc, H2 2016 292

Glioblastoma Multiforme (GBM) – Pipeline by Vaximm AG, H2 2016 293

Glioblastoma Multiforme (GBM) – Pipeline by VBI Vaccines Inc, H2 2016 294

Glioblastoma Multiforme (GBM) – Pipeline by VCN Biosciences SL, H2 2016 295

Glioblastoma Multiforme (GBM) – Pipeline by Vertex Pharmaceuticals Inc, H2 2016 296

Glioblastoma Multiforme (GBM) – Pipeline by ViraTherapeutics GmbH, H2 2016 297

Glioblastoma Multiforme (GBM) – Pipeline by Virttu Biologics Ltd, H2 2016 298

Glioblastoma Multiforme (GBM) – Pipeline by Vyriad Inc, H2 2016 299

Glioblastoma Multiforme (GBM) – Pipeline by X4 Pharmaceuticals Inc, H2 2016 300

Glioblastoma Multiforme (GBM) – Pipeline by ZIOPHARM Oncology Inc, H2 2016 301

Assessment by Monotherapy Products, H2 2016 302

Assessment by Combination Products, H2 2016 303

Number of Products by Stage and Target, H2 2016 305

Number of Products by Stage and Mechanism of Action, H2 2016 323

Number of Products by Stage and Route of Administration, H2 2016 341

Number of Products by Stage and Molecule Type, H2 2016 343

Glioblastoma Multiforme (GBM) – Dormant Projects, H2 2016 1284

Glioblastoma Multiforme (GBM) – Dormant Projects (Contd..1), H2 2016 1285

Glioblastoma Multiforme (GBM) – Dormant Projects (Contd..2), H2 2016 1286

Glioblastoma Multiforme (GBM) – Dormant Projects (Contd..3), H2 2016 1287

Glioblastoma Multiforme (GBM) – Dormant Projects (Contd..4), H2 2016 1288

Glioblastoma Multiforme (GBM) – Dormant Projects (Contd..5), H2 2016 1289

Glioblastoma Multiforme (GBM) – Dormant Projects (Contd..6), H2 2016 1290

Glioblastoma Multiforme (GBM) – Dormant Projects (Contd..7), H2 2016 1291

Glioblastoma Multiforme (GBM) – Dormant Projects (Contd..8), H2 2016 1292

Glioblastoma Multiforme (GBM) – Dormant Projects (Contd..9), H2 2016 1293

Glioblastoma Multiforme (GBM) – Dormant Projects (Contd..10), H2 2016 1294

Glioblastoma Multiforme (GBM) – Dormant Projects (Contd..11), H2 2016 1295

Glioblastoma Multiforme (GBM) – Dormant Projects (Contd..12), H2 2016 1296

Glioblastoma Multiforme (GBM) – Dormant Projects (Contd..13), H2 2016 1297

Glioblastoma Multiforme (GBM) – Dormant Projects (Contd..14), H2 2016 1298

Glioblastoma Multiforme (GBM) – Dormant Projects (Contd..15), H2 2016 1299

Glioblastoma Multiforme (GBM) – Dormant Projects (Contd..16), H2 2016 1300

Glioblastoma Multiforme (GBM) – Discontinued Products, H2 2016 1301

Glioblastoma Multiforme (GBM) – Discontinued Products (Contd..1), H2 2016 1302

Glioblastoma Multiforme (GBM) – Discontinued Products (Contd..2), H2 2016 1303

List of Figures

List of Figures

Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2016 54

Number of Products under Development for Glioblastoma Multiforme (GBM) – Comparative Analysis, H2 2016 55

Number of Products under Development by Companies, H2 2016 56

Number of Products under Investigation by Universities/Institutes, H2 2016 74

Comparative Analysis by Late Stage Development, H2 2016 77

Comparative Analysis by Clinical Stage Development, H2 2016 78

Comparative Analysis by Early Stage Products, H2 2016 79

Assessment by Monotherapy Products, H2 2016 302

Assessment by Combination Products, H2 2016 303

Number of Products by Top 10 Targets, H2 2016 304

Number of Products by Stage and Top 10 Targets, H2 2016 304

Number of Products by Top 10 Mechanism of Actions, H2 2016 322

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 322

Number of Products by Top 10 Routes of Administration, H2 2016 340

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 340

Number of Products by Top 10 Molecule Types, H2 2016 342

Number of Products by Stage and Top 10 Molecule Types, H2 2016 342

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports